Praxis Precision Medicines (PRAX) risk factors, FY2025 10-K

Risks Related to Past Financial Condition

1. 01We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We may incur significant losses for the foreseeable future25% rewritten

Risks Related to Future Financial Condition

1. 02We may need additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts
2. 03Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates86% rewritten
3. 04We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability45% rewritten
4. 05Drug development is a highly uncertain undertaking and involves a substantial degree of risk
5. 06We may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success

Risks Related to Preclinical and Clinical Development

1. 07Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following regulatory approval, if obtained87% rewritten
2. 08composition of our product candidates or learnings in preclinical studies or clinical trials may result in contraindications for any product candidates for which we may obtain regulatory approvalNew
3. 09If we encounter difficulties enrolling patients in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected
4. 10Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data
5. 11The markets for our product candidates may be smaller than we expect
6. 12We may not be successful in our efforts to identify or discover additional product candidates in the future
7. 13We conduct clinical trials for our product candidates in the United States, Europe and other jurisdictions, and the FDA, the European Medicines Agency, or EMA, and applicable foreign regulatory authorities may not accept data from trials conducted outside those respective jurisdictions72% rewritten
8. 14A Breakthrough Therapy designation from the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive FDA approvalNew
9. 15We received rare pediatric disease designation for relutrigine and elsunersen. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher28% rewritten

Risks Related to Regulatory Approval

1. 16Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
2. 17Our product candidates may be regulated as controlled substances, the making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration, or DEA, and other regulatory agencies56% rewritten
3. 18liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resourcesNew

Risks Related to Post-Marketing Regulatory Requirements

1. 19The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability

Risks Related to Sales, Marketing and Competition

1. 20Our commercial success depends upon attaining significant market acceptance of our drug product candidates, if approved, among physicians, patients, third-party payors and other members of the medical community
2. 21If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market acceptance and commercial success would be reduced
3. 22Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any
4. 23Even if we obtain approval of any of our product candidates in the United States or Europe, we may never obtain approval or commercialize such products in other countries, which would limit our ability to realize their full market potential60% rewritten

Risks Related to Healthcare and Related Laws

1. 24government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and businessNew
2. 25affected by the CCPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial conditionNew
3. 26Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations36% rewritten

Risks Related to International Regulations

1. 27EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states22% rewritten
2. 28Additional laws and regulations governing international operations could negatively impact or restrict our operations
3. 29If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business

Risks Related to Licensed Intellectual Property

1. 30Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection
2. 31We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates

Risks Related to License and Collaboration Agreements

1. 32Our technology licensed from third parties may be subject to retained rights79% rewritten
2. 33whether any future licensors will limit their use of the technology to these uses, and we may incur substantial expenses to enforce our rights to our licensed technology in the event of misuseNew
3. 34We may rely on trade secrets and proprietary know-how, which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets and proprietary know-how, our business and competitive position would be harmed

Risks Related to Potential Third-Party Claims

1. 35Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts
2. 36Our collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop or otherwise arising from the collaboration53% rewritten
3. 37We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
4. 38Third parties may assert that we are employing their proprietary technology without authorization
5. 39Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
6. 40Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights
7. 41We may be involved in lawsuits to protect or enforce our patents or other intellectual property, or the patents or intellectual property of our licensors, which could be expensive, time-consuming and unsuccessful
8. 42owned by or in-licensed to us, we may incur substantial costs, divert management’s time and expend other resources, even if we are successfulNew

Risks Related to Patent Laws and Protection

1. 43Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
2. 44Any patents, if issued, covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO
3. 45Changes in patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
4. 46We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world35% rewritten
5. 47be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or licenseNew
6. 48Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
7. 49If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed
8. 50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks Related to Third-Party Manufacturers

1. 51Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis
2. 52If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product may increase and commercialization may be delayed

Risks Related to Third-Party Suppliers

1. 53We depend on third-party suppliers for key raw materials used in our manufacturing processes, some of which are our sole source of supply, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business
2. 54We depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates
3. 55We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions or alliances

Risks Related to Business Operations

1. 56Our business is subject to economic, political, regulatory and other risks associated with international operations
2. 57We or the third parties upon whom we depend may be adversely affected by natural disasters, health epidemics or other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster39% rewritten

Risks Related to Employees

1. 58We depend heavily on our executive officers, principal consultants and others, and the loss of their services could materially harm our business32% rewritten
2. 59individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully
3. 60Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation
4. 61We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations40% rewritten

Risks Related to Data Privacy and Cybersecurity

1. 62sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systemsNew
2. 63We rely on cloud-based software services and access these services via the Internet for the vast majority of our computing, storage, and other functions. Any disruption of or interference with our use of our cloud-based services would negatively affect our operations and could seriously harm our businessNew

Risks Related to Tax Laws

1. 64Legislation or other changes in tax laws could adversely affect our business and financial condition29% rewritten
2. 65Our ability to use our U.S. federal and state net operating loss carryforwards and certain other tax attributes may be limited

Risks Related to Investment in Securities

1. 66The price of our stock has been and may in the future be volatile, and you could lose all or part of your investment
2. 67If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
3. 68We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
4. 69Future issuances of our common stock or the issuance of shares of common stock upon the exercise or conversion of securities that are exercisable or convertible into shares of common stock, such as our pre-funded warrants, or upon the exercise or vesting of incentive awards, may result in dilution for our stockholders
5. 70Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders
6. 71Our executive officers and directors and principal stockholders own a significant percentage of our stock and may exert significant influence over matters subject to stockholder approval27% rewritten

Risks Related to Our Controls and Reporting Requirements

1. 72We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives46% rewritten
2. 73Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
3. 74We have broad discretion over the use of our cash, cash equivalents and marketable securities and may not use them effectively32% rewritten

Risks Related to Charter and Bylaws

1. 75Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
2. 76stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employeesNew